WP02 Continued Access Study
Continued Access Protocol Study for the Use of the OrganOx Metra Normothermic Machine Perfusion Device in Human Liver Transplantation
Sponsor: North American Science Associates Ltd.
Terminated
FDA agreed that WP02 CAP could be stopped. The OrganOx metra device was approved on December 9, 2021. The 105 planned CAP patients will be included in the Post-Approval study (NCT05526326).
Listed as NCT04862156, this NA trial focuses on Liver Transplantation and remains terminated or withdrawn. Sponsored by North American Science Associates Ltd., it has been updated 16 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Terminated NA
-
May 2025 — Sep 2025 [monthly]
Terminated NA
-
Sep 2024 — May 2025 [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Mar 2024 — Jul 2024 [monthly]
Terminated NA
▶ Show 11 earlier versions
-
Dec 2023 — Mar 2024 [monthly]
Terminated NA
Status: Active Not Recruiting → Terminated
-
Apr 2023 — Dec 2023 [monthly]
Active Not Recruiting NA
-
Dec 2022 — Apr 2023 [monthly]
Active Not Recruiting NA
-
Sep 2022 — Dec 2022 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
May 2022 — Sep 2022 [monthly]
Recruiting NA
-
Apr 2022 — May 2022 [monthly]
Recruiting NA
-
Mar 2022 — Apr 2022 [monthly]
Recruiting NA
Status: Withheld → Recruiting · Phase: None → NA
-
Dec 2021 — Mar 2022 [monthly]
Withheld
-
Nov 2021 — Dec 2021 [monthly]
Withheld
-
Oct 2021 — Nov 2021 [monthly]
Withheld
-
May 2021 — Oct 2021 [monthly]
Withheld
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- North American Science Associates Ltd.
- OrganOx Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .